Recordati Industria Chimica e Farmaceutica SpA (RECI.MI) Key Developments | Reuters.com
Edition:
United States

Recordati Industria Chimica e Farmaceutica SpA (RECI.MI)

RECI.MI on Milan Stock Exchange

27.03EUR
1 Jul 2016
Change (% chg)

€0.03 (+0.11%)
Prev Close
€27.00
Open
€27.00
Day's High
€27.30
Day's Low
€27.00
Volume
403,436
Avg. Vol
428,801
52-wk High
€27.74
52-wk Low
€18.50

Latest Key Developments (Source: Significant Developments)

Italy's Recordati buys Italchimici in deal valued at 130 mln euros
Tuesday, 31 May 2016 10:05am EDT 

Italy's Recordati Industria Chimica E Farmaceutica says: has bought all of Italian pharmaceutical company Italchimici . deal valued at about 130 million euros .to be funded in cash.  Full Article

Recordati Industria Chimica E Farmaceutica SpA proposes dividend on 2015 of 0.60 euros per share
Tuesday, 8 Mar 2016 08:04am EST 

Recordati Industria Chimica E Farmaceutica SpA:Proposes dividend on 2015 of 0.60 euro per share, of which 0.30 euro already paid.  Full Article

Recordati Industria Chimica e Farmaceutica SpA confirms FY 2015 outlook in line with analysts' estimates, proposes interim 2015 dividend
Wednesday, 28 Oct 2015 07:21am EDT 

Recordati Industria Chimica e Farmaceutica SpA:Confirms to achieve FY 2015 sales of around 1.04 billion euros.Confirms FY 2015 operating income of around 270 million euros.Confirms FY 2015 net income of around 190 million euros.Reported FY 2014 revenue at 987.4 million euros.Reported FY 2014 operating profit at 231.0 million euros.Reported FY 2014 net profit of 161.2 million euros.FY 2015 revenue of 1.04 billion euros - Thomson Reuters I/B/E/S.FY 2015 operating profit of 273.1 million euros - Thomson Reuters I/B/E/S.FY 2015 net profit of 193.9 million euros - Thomson Reuters I/B/E/S.Proposes 2015 interim dividend of 0.30 euros per share.  Full Article

Recordati Industria Chimica E Farmaceutica SpA: unit says Canada grants market authorization for Carbaglu
Tuesday, 8 Sep 2015 08:00pm EDT 

Recordati Industria Chimica E Farmaceutica SpA:Company's unit Orphan Europe says Health Canada has granted market authorization for Carbaglu.Authorization for Carbaglu was granted as an adjunctive therapy for the treatment of acute hyperammonemia (high blood level of ammonia) or as a maintenance therapy for chronic hyperammonemia due to the deficiency of the hepatic enzyme N-aceytlglutamate synthase (NAGS) in pediatric and adult patients.Carbaglu will be imported and distributed in Canada by unit Recordati Rare Diseases Inc.  Full Article

Recordati Industria Chimica e Farmaceutica SpA reviews FY 2015 targets upwards
Wednesday, 29 Jul 2015 05:04am EDT 

Recordati Industria Chimica e Farmaceutica SpA:"The group's business performance during July was in line with the first half and consequently targets for the full year 2015 were reviewed upwards of those announced on 12 February 2015" - CEO and chairman Giovanni Recordati.Expects FY 2015 sales of around 1,040 million euros.Expects FY 2015 operating income of around 270 million euros.Expects FY 2015 net income of around 190 million euros.Reported FY 2014 net profit of 161.20 million euros.FY 2015 net profit of 191.32 million euros - Thomson Reuters I/B/E/S.  Full Article

Recordati Industria Chimica E Farmaceutica SpA reaffirms FY 2015 revenue guidance
Tuesday, 5 May 2015 05:32am EDT 

Recordati Industria Chimica E Farmaceutica SpA:Reaffirms FY 2015 revenue of over 1 billion euros.FY 2015 revenue of 1.04 billions - Thomson Reuters I/B/E/S.  Full Article

Recordati Industria Chimica E Farmaceutica SpA proposes FY 2014 dividend
Wednesday, 4 Mar 2015 06:47am EST 

Recordati Industria Chimica E Farmaceutica SpA:Proposes FY 2014 dividend of 0.50 euro per share, of which 0.26 euro per share has already been paid (FY 2013: 0.33 euro per share).FY 2014 dividend to be paid on April 22, and record date on April 21.  Full Article

Recordati Industria Chimica E Farmaceutica SpA gives FY 2015, 2017 outlook
Thursday, 12 Feb 2015 06:31am EST 

Recordati Industria Chimica E Farmaceutica SpA:Expects FY 2015 sales to be more than 1,000 mln Euro.Expects FY 2015 EBIT of around 250 mln Euro.Expects FY 2015 net income of 175 mln Euro.Expects FY 2017 revenues of around 1,150 mln Euro.Expects FY 2017 EBIT margin of between 25 and 26 pct.Expects FY 2017 net income margin of between 17 and 18 pct.FY 2015 revenue of 1,047 mln Euro, EBIT of 245 mln Euro, net income of 175 mln Euro - Thomson Reuters I/B/E/S.FY 2017 revenue of 1,049 mln Euro - Thomson Reuters I/B/E/S.  Full Article

Recordati Industria Chimica E Farmaceutica SpA reaffirms FY 2014 revenue guidance; updates FY 2014 earnings guidance
Tuesday, 28 Oct 2014 07:42am EDT 

Recordati Industria Chimica E Farmaceutica SpA:Targets FY 2014 to achieve sales of slightly below 1.000 billion euros, operating income of around 230 million euros and net income of around 160 million euros.  Full Article

Recordati Industria Chimica E Farmaceutica SpA to pay interim dividend
Tuesday, 28 Oct 2014 07:42am EDT 

Recordati Industria Chimica E Farmaceutica SpA:Board of Directors resolved to distribute an interim dividend relating to financial year 2014 amounting to 0.26 euro (before withholding tax) on each outstanding share, excluding shares in treasury stock.The interim dividend will be paid, through authorised intermediaries, as from Nov.19 (record date Nov. 18) on coupon No. 14 to be presented on Nov. 17.  Full Article